Skip to content

Hiromasa Morikawa

  • MD. Ph.D.
  • Medical Doctor
  • Tanaka Clinic (Kyoto JP)
  • 9h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 1590CitationsNumber of citations received by Hiromasa's publications. Updated daily.


After medical school, I was working as a chest surgeon from 2001 to 2009. Throughout my career as a surgeon treating tumours and involved in lung transplantations, I was in a quandary over seemingly opposing immunological issues. In tumour immunotherapy it was implausible to activate tumour-specific immune responses, and conversely, in transplantation it was unfeasible to suppress allograft specific immune response. By studying the function and generation of regulatory T cells, it may be possible to establish a method for controlling antigen specific immune responses by inducing or blocking activities of regulatory T cells and improving the prognosis of advanced cancer and transplantation. For this purpose, I have decided to attend graduate program at Kyoto University to study Tregs and immunology and was fortunate enough to join Dr. Shimon Sakaguchi's laboratory. I’ve been studying gene regulation of regulatory T-cell and transplantation tolerance. I've utilized next generation sequencer, as a part of Fantom5 project, to analyse the relationship between genome wide epigenetic patterns, transcription start sites and their expression in T-cells. Furthermore, I expanded my project by using a newly generated mouse to establish a model of transplantation tolerance. After PhD course, I move my focus from completely WET research to WET&DRY combination research. For this aim, I move to Karolinska Institutet to join Unit of Computational medicine, which consist of many mathematician and WET researchers. now I am working on single cell analysis on both WET and DRY, targeting human cells. These WET&DRY technology will contribute to human health care and improve medical treatment.

Recent publications

  • Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma

    • Rad Pour S
    • Morikawa H
    • Kiani N
    • et al.
  • Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.

    • Tanaka A
    • Nishikawa H
    • Noguchi S
    • et al.

Professional experience

Medical Doctor

Tanaka Clinic (Kyoto JP)

March 2019 - Present

Science Lead

AstraZeneca KK

September 2017 - March 2019(2 years)

Vinnmer-Marie Curie Fellow

Karolinska Institutet

January 2015 - September 2017(3 years)

Posdoc researcher

Karolinska Institutet

August 2014 - December 2014(4 months)

Assistant Professor / Research Unit Co-leader

Osaka University

April 2014 - July 2014(3 months)

Specially appointed researcher

Osaka University

April 2012 - March 2014(2 years)

Medical Doctor (Department of Thoracic surgery)

Kyoto University Hospital

April 2001 - March 2008(7 years)


PhD (Nov 2013)

graduate school of medicine, Kyoto university

April 2008 - March 2012(4 years)

MD (Apr 2001)

Kyoto University, Medical School

April 1995 - March 2001(6 years)


Co-authors (336)

Other IDs